Dr. Mehta-Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2012
- Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
- IL State Medical License 2020 - 2026
- MO State Medical License 2016 - 2025
- NY State Medical License 2011 - 2018
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Minimal Residual Disease in Peripheral T-cell Lymphoma Start of enrollment: 2017 Jul 31
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Start of enrollment: 2021 Jul 30
Roles: Principal Investigator, Contact, Study Chair
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Start of enrollment: 2021 Apr 29
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 126 citationsThe Genetic Basis of Hepatosplenic T-cell LymphomaMatthew McKinney, Andrea B. Moffitt, Philippe Gaulard, Marion Travert, Laurence de Leval
Cancer Discovery. 2017-04-01 - 3 citationsPrognosis and risk stratification of peripheral T-cell lymphomas.Mary-Kate Malecek, Neha Mehta-Shah
Seminars in Hematology. 2021-02-11 - 33 citationsNCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Jeffrey A. Barnes, Stefan K. Barta
Journal of the National Comprehensive Cancer Network. 2020-11-02
Abstracts/Posters
- Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Aggressive Non-Hodgkin Lymphomas: It's Getting Personal61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Black Patients with CLL Face Shorter Overall SurvivalJune 5th, 2022
- What Is the Optimal Frontline Treatment for PTCL?June 23rd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: